Agenus to Host Annual Meeting of Stockholders
LEXINGTON, Mass. -- April 16, 2014
Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to its
Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, April
23, 2014. The meeting will be held at the company's headquarters located at 3
Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30
The company will also broadcast the meeting via a virtual stockholder meeting.
Instructions on how to participate and demonstrate proof of stock ownership
are posted at www.virtualshareholdermeeting.com/Agenus2014.
A live webcast will be accessible from the company’s website at
www.agenusbio.com/webcast/ and will be archived and available for replay
within twenty-four hours after the meeting.
Agenus is an immuno-oncology company developing a portfolio of checkpoint
modulators, heat shock protein vaccines and adjuvants. Agenus’ checkpoint
modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The
company’s proprietary discovery engine Retrocyte Display^® is used to generate
fully human therapeutic antibody drug candidates. The Retrocyte Display
platform uses a high-throughput approach incorporating full-length IgG format
human antibody libraries expressed in mammalian B-lineage cells. Agenus’ heat
shock protein vaccines for cancer and infectious disease are in Phase 2
studies. The company’s QS-21 Stimulon^® adjuvant platform is extensively
partnered with GlaxoSmithKline and Janssen, and includes several candidates in
Phase 3 trials. Among Agenus and its partners, 22 programs are in clinical
development. For more information, please visit www.agenusbio.com, or connect
with the company on Facebook, LinkedIn, Twitter and Google+.
QS-21 Stimulon and Retrocyte Display are registered trademarks of Agenus and
Media and Investor Contact:
Jonae R. Barnes, 781-674-4538 Office
Investor Relations and Corporate Communications
Press spacebar to pause and continue. Press esc to stop.